October 31, 2024

Award-winning research in emergency medicine in Heidelberg

Award-winning research in emergency medicine in Heidelberg

Research is constantly being conducted at Heidelberg University Hospital to continuously improve patient care and patient safety. The emergency medicine department has already received several awards for its innovations and improvements.

Dr. Stephan Katzenschlager is deputy research group leader of the Emergency Medicine Section at the Department of Anaesthesiology at the UKHD. His research has already won several awards. The Medical Intervention Car, a specially equipped rescue vehicle, can be seen in the background. Photo: Heidelberg University Hospital

The Emergency Medicine Section of the Department of Anesthesiology at Heidelberg University Hospital (UKHD) recently received the Rudolf Frey Prize 2024 from the German Society of Anesthesiology and Intensive Care Medicine. The team led by Dr. Stephan Katzenschlager, Dr. Stefan Mohr, Nikolai Kaltschmidt and Professor Dr. Erik Popp received the award for their research in the field of emergency medicine entitled “Laryngeal mask vs. laryngeal tube trial in paediatric patients (LaMaTuPe): a single-blinded, open-label, randomized controlled trial”. In it, they investigated airway management in children and adolescents by looking at the safety and effectiveness of modern airway devices.

The team compared the use of a laryngeal mask with the use of a laryngeal tube, both of which play a crucial role in ensuring effective ventilation, particularly in emergencies. Until now, the standard procedure for securing the airway was to insert a tube into the windpipe (known as endotracheal intubation). This procedure is still the most reliable method, but requires a lot of practice and experience on the part of the treating staff. As children have an even lower tolerance to oxygen deprivation than adults and are therefore particularly at risk, the team focused on this important area in their award-winning research work. The research on airway safety showed that the laryngeal mask is clearly superior to the laryngeal tube due to the shorter insertion time. The insertion time of the mask was 31 seconds, that of the tube 37 seconds. Seconds that can make the difference between life and death. The mask also performed better than the tube in terms of the success rate of the first insertion and led to fewer complications – such valuable findings for clinical practice make a decisive contribution to making emergency care safer when securing the airways of children and adolescents.

Dr. Katzenschlager was awarded the German Resuscitation Prize back in 2023. In his award-winning research work, he looked at out-of-hospital cardiac arrests in children and searched for factors that increase the chances of survival. Katzenschlager has also received financial support for his scientific work from the Heidelberg Surgery Foundation twice, in 2022 and 2024.

Original News

Our latest News

discover more
Antitrust hurdle cleared: Important milestone on the way to the Heidelberg-Mannheim hospital network

Antitrust hurdle cleared: Important milestone on the way to the Heidelberg-Mannheim hospital network

At the request of Heidelberg University Hospital, the Ministry of Social Affairs, Health and Integration has confirmed that the merger of the two university hospitals in Heidelberg and Mannheim is deemed necessary to improve hospital care and that the merger does not conflict with any other competition law regulations. Press release from the Ministry of […]

Childhood brain tumors develop early in highly specialized nerve cells

Childhood brain tumors develop early in highly specialized nerve cells

Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have now published their findings in the journal Nature. They […]

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

The partnership combines VERAXA’s proprietary ADC technology with OmniAb’s antibody discovery technology for novel therapies targeting solid tumors. ZURICH, SWITZERLAND, May 5, 2025 — VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp